Sarepta: the operating-spend boundary
Sarepta’s Q2 outlook puts combined non-GAAP R&D and SG&A at $800M–$850M. The $825M midpoint tracks the cost base independently from sales.
Sarepta Therapeutics / SRPTPublic biotechR&D-spendingDate to watch
What matters
Track what the company has actually announced, the study or asset involved, and the evidence needed to confirm the milestone.
- The Q2 outlook may have been superseded by later disclosures.
Primary evidence
Reporting date unconfirmed — research candidate
Sarepta Q2 2026 results and outlookCompany source
Potential outcome market
Will Sarepta combined non-GAAP R&D and SG&A exceed $825 million in 2026?
This event is research, not a listed market. A market needs a precise question, resolution rules and liquidity before trading opens.